PITTSBURGHThe National Surgical Adjuvant Breast and Bowel
Project (NSABP) is encouraging women from racial and ethnic minority
groups to consider joining the groups Study of Tamoxifen and
The study will compare the proven benefits of tamoxifen (Nolvadex) in
reducing the incidence of breast cancer in healthy high-risk women
against the promising effects of raloxifene (Evista), which is FDA
approved to prevent and treat osteoporosis in postmenopausal women.
Over a 5-year period, STAR will enroll 22,000 women. As of March 31,
2000, 4,598 women had joined and 4% are from a racial or ethnic
The NSABP has a special educational effort underway, SCOPEthe
STAR Community Outreach Program for Educationto address myths
in the minority community about breast cancer and to encourage more
minority women to participate in clinical trials.